

TREATMENTS FOR DIABETES

6-9 MARCH 2024 FLORENCE & ONLINE

PRELIMINARY PROGRAM*

*Subject to change

Wednesday, 6 March, 2024

| 13:00-14:30 | PLENARY INDUSTRY SYMPOSIUM (not included in the main | event CME/CPD credit) | | | | | |
|-------------|---|--|--|--|--|--|--|
| 14:30–14:40 | | Break to Change Halls | | | | | |
| 14:40-16:10 | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | | | |
| 16:10-16:20 | | Break to Change Halls | | | | | |
| 16:20-17:50 | PLENARY INDUSTRY SYMPOSIUM (not included in the main | event CME/CPD credit) | | | | | |
| 18:00-19:00 | OPENING CEREMONY OPENING LECTURE <u>Melanie Davis</u> – TBC | | | | | | |
| 19:00-20:00 | NETWORKING RECEPTION (in the Exhibition Area) | | | | | | |

Thursday, 7 March, 2024

| 09:00- 10:00 | | | | | | | | | |
|-----------------|--|---|--|---|---|--|------------|--|--|
| 10.00 | Moshe Phillip - From d | ream to reality - The Automate | ed Insulin Delivery (AID) sys | tem | | | | | |
| | Boris Kovatchev - Neu | ral-Net artificial pancreas | | | | | | | |
| | <u>Camillo Ricordi</u> - From and possible solutions | the first-in-human success in s | stem cell derived Islet Trans | plantation to a cure for all | patients with diabetes: Chall | enges, requireme | ents, | | |
| 10:00- 10:30 | COFFEE BREAK, EXHIB | ITION & E-POSTERS | | | | | | | |
| 10:30- 12:00 | | | | | | | | | |
| 12:00- 13:00 | 2- LUNCH BREAK, EXHIBITION & E-POSTERS | | | | | | | | |
| 13:00- 14:30 | PARALLEL SESSION 1 AUTOMATED INSULIN DELIVERY IN TYPE 1 AND TYPE 2 DIABETES | PARALLEL SESSION 2 SCREENING, INTERVENTION AND PREVENTION OF TYPE 1 DIABETES (1) | PARALLEL SESSION 3 CGM DIABETES QUALITY MEASURES | PARALLEL SESSION 4 COPING WITH OBESITY | PARALLEL SESSION 5 HYPOGLYCEMIA - ANY PROGRESS? | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | Orals 1 | | |
| | Anders Carlson – Use | <u> Teresa Rodriguez-Calvo</u> - | <u>Irl Hirsch</u> - What has | <u>Emma Wilmot</u> – | Stephanie Amiel – CGM | | | | |
| | of AID in patients with | Role of viruses in | the GMI taught us about | Technology-supported | detection of | | | | |
| | type 2 diabetes | pathogenesis of type 1 | A1C? | behavior intervention in | hypoglycemia in diabetes | | | | |
| | <u>Roman Hovorka</u> - | diabetes | <u>Elisabeth Selvin</u> - | type 2 diabetes (STAND) | management | | | | |
| | Fully closed-loop in | <u>Stefan Bornstein</u> - Islet | Should A1C still be a | <u> Kamlesh Khunti</u> - Early | <u>Simon Heller</u> - Should | | | | |
| | type 1 and type 2 | Transplantation 2024 | diagnostic criterion for | intervention for type 2 | the classification of | | | | |
| | diabetes | <u>Roberto Mallone</u> - Benign | diabetes in 2024? | diabetes in primary care | hypoglycemia be | | | | |
| | Bruce Bode - | autoimmunity & | <u>Gregg Simonson</u> – | <u>Max Nieuwdorp</u> - A | updated? | | | | |
| | Management of | progression to type 1 | CGM (GMI/TIR) as | balanced view on | Pratik Choudhary - | | | | |
| | glucose in the hospital | diabetes | diabetes quality metrics | microbiome in obesity | Implication of | | | | |
| | with AID systems | <u>Desmond Schatz</u> – | Guido Freckmann - | <u>Luca Busetto</u> – Will new | HypoMETRICS for | | | | |
| | Samantha Roberts - | Enhancing our | International standard | pharmacological | reporting hypoglycemia | | | | |
| | Bringing science into | understanding of why type | for evaluation of CGM | treatment for obesity | in clinical trials | | | | |
| | lives: a NICE | 1 diabetes develops. | systems: Approach of | and early diabetes | Bastiaan de Galan - | | | | |
| | perspective | Lessons learned from organ | the IFCC | replace bariatric | Impaired awareness of | | | | |
| | | donors | | surgery? | hypoglycemia | | | | |

| PLENARY INDUSTRY S | YMPOSIUM (not included | in the main event CME/CPD of | credit) | | | | |
|--|--|---|--|--|--|--|----------|
| COFFEE BREAK, EXHIBI | | | | | | | |
| PARALLEL SESSION 6 STANDARDIZATION OF PROS | PARALLEL SESSION 7 ACCESSIBILITY AND DISPARITIES OF DIABETES THERAPY | PARALLEL SESSION 8 ROLE OF TECHNOLOGY IN NORMAL HEALTHY AND IN GDM PREGNANCY | PARALLEL SESSION 9 HYBRID CLOSED- LOOP FOR TYPE 2 DIABETES: HURDLES AND BENEFITS | PARALLEL SESSION 10 THE EFFECT OF DIABETES ON BRAIN HEALTH | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | Ora 2 |
| Oliver Schnell - What PROs mean in routine clinical care Katharine Barnard- Kelly - Consensus statement summary, navigating the maze of PROs Mary Murphy - What inclusion of quality PRO assessment in clinical trials means to people with diabetes Alon Liberman – Real world data from type 1 diabetes clinics | Lori Laffel - Interventions to reduce health disparities in diabetes device use V Mohan – Innovating to use existing technologies under resourced settings Partha Kar - Widening clinical use of diabetes tech in the UK Stuart Weinzimer - Strategies to facilitate technology use in disadvantaged youth with diabetes Ananta Addala - Solutions for equity: A call to action | Celeste Durnwald – Can CGM replace the oral glucose tolerance test for diagnosis of Gestational diabetes? Eleanor Scott - CGM glucose trajectories associated with large and small for gestational age birthweight Helen Murphy – Should everyone with type 1 diabetes be offered closed-loop during pregnancy? Yariv Yogev - Should all women with diabetes in pregnancy undergo induction of labor at 38 weeks of gestation? | Yves Reznik - Closed-loop as home care for type 2 diabetes: The Close study Charlotte Boughton - Cumulated experience with CamAPS in type 2 diabetes Gregory Forlenza - Real-world data on hybrid closed-loop (HCL) in type 2 diabetes Anne Peters - Pod use for closed-loop in type 2 diabetes | Mark Strachan - Update on diabetes- associated cognitive dysfunction Tali Cukierman- Yaffe - Diagnosis & monitoring of brain health in people with diabetes Hertzel Gerstein - Brain aging in people with diabetes - Possible intervention TBC - Novel approaches and the role of technology in treating brain aging in people with diabetes | | | |

Friday, 8 March, 2024

| 08:30- 09:20 | PLENARY INDUSTRY S | YMPOSIUM (not included | in the main event CME/CPD credit) | | | | |
|-----------------|---|---|---|--|---|--|------------|
| 09:20- 09:30 | Break to change halls | | | | | | |
| 09:30- 10:30 | PARALLEL SESSION 11 PRACTICAL USE OF CGM | PARALLEL SESSION 12 WEEKLY INSULINS | PARALLEL SESSION 13 SKIN PROBLEMS IN DIABETES | PARALLEL SESSION 14 DUAL AND TRIPLE AGONISTS IN DIABETES | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | ORALS 3 |
| | Laurel Messer - Technology pearls for professionals | <u>Julio Rosenstock</u> – Update on weekly insulin Icodec: The | Anna Korsgaard Berg - Skin problems caused by diabetes devices | <u>Viral Shah</u> – GLP-1RA and SGLT in type 1 diabetes | | | |
| | <u>Steven Edelman</u> – Top 10 tips to help people with diabetes (PwD) stay in range | way of the future Juan Frias – Update on weekly insulin Efsitora | Julia Mader Lipohypertrophy and its effect on glucose control/insulin | Andrej Janež – Incretins and taste TBC | | | |
| | <u>Steven Edelman and</u> <u>Jeremy Pettus</u> – Rapid fire | <u>Chantal Mathieu</u> – CGM derived data on weekly insulins | uptake/causes/detection/trai ning and awareness of HCP and PwD | | | | |
| | interpretations of CGM downloads | | Deirdre Fitzgerald Huges - Shining a light on diabetic foot infections, development of novel photodynamic materials | | | | |
| 10:30- 11:00 | COFFEE BREAK, EXHIB | ITION & E-POSTERS | | | | | |
| 11:00- 12:30 | PLENARY INDUSTRY S | YMPOSIUM (not included | in the main event CME/CPD credit) | | | | |
| 12:30- 13:30 | LUNCH BREAK, EXHIB | ITION & E-POSTERS | | | | | |

| 5:00- 5:15 5:15- | Break | RY SYMPOSIUM (not ind | duded in the main event | | | | | |
|-------------------------------|--|--|---|---|---|--|--|-------|
| 5:45 5:45- | | HIBITION & E-POSTEI | | | | | | |
| 7:15 7:15- 3:45 | PARALLEL SESSION 15 OBESITY IN TYPE 1 DIABETES | PARALLEL SESSION 16 AUTOMATED INSULIN DELIVERY IN CHILDREN | PARALLEL SESSION 17 INTEROPERABILITY OF DIABETES TECHNOLOGY | PARALLEL SESSION 18 CGM GUIDED PRECISION DIABETES MANAGEMENT | PARALLEL SESSION 19 SELF MANAGEMENT OF DIABETES (17:15-18:05) | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit) | ORALS |
| | Satish Garg - Management options for treating obesity in type 1 diabetes patients Jeremy Pettus - Insulin resistance in type 1 diabetes: An underappreciated problem Kirsten Nørgaard - Effects of GLP1 in type 1 diabetes TBC | Revital Nimri - Maximizing glycemic control with automated insulin delivery in young children Thomas Danne – Worldwide progress achieving treatment targets in children with type 1 diabetes Ivana Rabbone - Technology in the changing management of diabetes in children Nataša Bratina - Data on diabetes treatment in children below the age of six | David Klonoff – Interoperability of diabetes technolog - Academic view Alexander Olbrechts - Interoperability of diabetes technolog - A company's view Johan Jendle – Interoperability of diabetes technology – Regulatory hurdle Tim Street – Interoperability of diabetes technology – Patient's view | nutrition <u>Michael Riddell</u> - CGM guided exercise Thomas | Mark Clements – Just in time adaptive interventions: The new technology to "hack" diabetes self- management behavior John Leth - The potential of open- source software in diabetes research Heiko Peuscher - A survey on existing open-source projects in diabetes simulation Short Break PARALLEL SESSION 20 TECH IT OUT OF THE BOX: PAPERS, POLICY, PATIENTS (18:15-18:45) Introduction Partha Kar - Challenges of getting technology into policy TBC - CGM in Pregnancy Jazz Sethi - D-Coding tech research into reality | | | |
| 8:45- 8:55 8:55- | Break to Change Hall | s RY SYMPOSIUM (not ind | cluded in the main event | CME/CPD credit) | | | | |

Saturday, 9 March, 2024

| Break to Change Halls PARALLEL SESSION 21 DECISION SUPPORT AND AUTOMATED INSULIN DELIVERY FOR THE MANAGEMENT OF TYPE 2 DIABETES | PARALLEL SESSION 22 SCREENING, INTERVENTION AND PREVENTION OF TYPE 1 DIABETES (2) | PARALLEL SESSION 23 CGM CLINICAL WORKFLOW | PARALLEL SESSION 24 NUTRITION AND FOOD TECHNOLOGIES | PARALLEL SESSION 25 CHALLENGES IN METABOLIC CONTROL | ORALS 5 | OR 6 |
|--|---|--|--|--|------------|---------|
| <u>Chiara Fabris</u> - Simulation- enhanced closed-loop adaptation of long-acting insulin dosing in T2D <u>Lia Bally</u> - Virtual clinic for insulin therapy in type 2 diabetes <u>Morten Hasselstrøm</u> <u>Jensen</u> - Adherence through cloud-based personalized treatment for Type 2 diabetes: The ADAPT-T2D project | Emanuele Bosi – Universal screening for risk of type 1 diabetes: Can it be an effective prevention tool? Laura Jacobsen – Immune therapy – Predicting responders/non- responders Jennifer Sherr – Teplizumab therapy in the real world Raffaella Buzzetti – Antibody positivity in adult population | David Maahs - Early CGM initiation in pediatric type 1 diabetes: Equity and logistical considerations from the 4T Study Amy Criego – CGM Success: Device start and ongoing data management to improve patient care TBC - Integration of CGM data into the EMR – Challenges and successes Xavier Cos - Use of CGM by the primary care providers | Laya Ekhlaspour - Beyond carbohydrate counting: Optimizing mealtime insulin dosing Peter Jacobs - Unannounced meal detection algorithms: Can we eliminate manual meal boluses? Michal Gillon-Keren - Facilitate carb counting for people with diabetes Daria Igudesman - Diet, microbiome, obesity and type 1 diabetes | <u>Richard Bergenstal</u> - We need to clear the FOG (Feet on the Ground) hyperglycemia in order to minimize hyperglycemia <u>Elisabeth Selvin</u> - Diabetes and cognitive decline and dementia <u>Francesco Giorgino</u> - Addressing glucose patterns in type 2 diabetes: Opportunities and challenges <u>Nebojsa Lalic</u> - Achievement of optimal time in range and glucose variability in pump treated type 1 diabetes patients with diabetic kidney disease | | |

| 11:30- 13:00 | PARALLEL SESSION 26 GENDER DIFFERENCES IN DIABETES MANAGEMENT AND GLUCOSE CONTROL | PARALLEL SESSION 27 SPORT IN DIABETES | PARALLEL SESSION 28 TO CGM OR NOT TO CGM? | PARALLEL SESSION 29 JDRF CELL REPLACEMENT THERAPY | PARALLEL 30 ADVANCES IN TREATING DIABETES | ORALS 7 | ORALS 8 |
|-----------------|--|--|--|--|--|------------|------------|
| | Eda Cengiz - Update on diabetes Female Technology (femtech) Chiara Fabris - What do women want (and need)? Results from the large-scale IMAGINE survey Jane Yardley - Challenges of exercise in women with type 1 diabetes Brynn Marks - Insulin delivery is automated, but the education is not: Mothering diabetes technology users | Klemen Dovc - Automated insulin delivery around exercise in type 1 diabetes: Individualization versus generalizability Michael Riddell - Lessons learned from the ongoing type 1 diabetes exercise research initiative Kirsten Nørgaard - Low-dose glucagon to prevent hypoglycemia during exercise Dessi Zaharieva - Translation of exercise guidelines into practical applications for type 1 diabetes | Tadej Battelino - CGM derived criteria for stage 2 type 1 diabetes Leon Farhy – Diagnostic CGM Anders Carlson - The use of CGM in prediabetes and obesity Dario Rahelic - Use of CGM in nutrition management in type 2 diabetes | TBC | Peter Adolfsson - Current use of connected pens Fernando Gómez Peralta - Connected Insulin Pens and Caps: An Expert's Recommendation from the Area of Diabetes of the Spanish Endocrinology and Nutrition Society (SEEN) Christophe de Block – Ketone continuous measurement – is it needed? Andrea Facchinetti - Digital twin Technologies for treating Diabetes <u>Neal Kaufman</u> - The importance and impact of family caregivers on a variety of outcomes for people with diabetes | | |
| 13:00- 13:45 | LUNCH BREAK, EXHIBITION 8 | k E-POSTERS | | | | | |

| 15:15 | PARALLEL SESSION 31 OBESITY IN TYPE 2 DIABETES | PARALLEL SESSION 32 DIABETES IN ITALY | PARALLEL SESSION 33 DTECH SYMPOSIUM - DIABETES IN INDIA | PARALLEL SESSION 34 ISPAD/ATTD SESSION DIABETES TECHNOLOGY IN LOWER INCOME COUNTRIES | PARALLEL SESSION 35 SARCOPENIA, FRAILTY AND DIABETES | ORALS 9 | ORALS 10 |
|-------|--|--|---|---|---|------------|-------------|
| | Antonio Ceriello - Weight and glycemic variability: Bad companions for CVD development in diabetes Barbara McGowan - Medical therapies for treatment of obesity Jernej Kovac - Genetic background of obesity TBC | Marco Marigliano - Relationships between insulin delivery system, CGM satisfaction and glucometrics Andrea Scaramuzza - Real- world data in very young AHCL users - Comparison among different systems Nicola Minuto - Sick days management using AHCL systems in pediatrics: What to do when the algorithm is not enough Sergio di Molfetta - CGM in type 2 diabetes patients: From professional use to experiences in patients not insulin treated | Banshi Saboo - Welcome and introduction to Dtech symposium Joshi Shashank - Artificial intelligence in diabetes care Jothydev Kesavadev - 25 years of telemedicine Vs conventional care in diabetes: assessing vascular complications and quality of life Manoj Chawla - Optimizing real time CGM in self-pay markets Amit Gupta - Challenges and opportunities in digital diabetes care in India Mithun Bhartia - Diabetes and sex life – The role of technology to improve quality of life Rakesh Parikh: Artificial Intelligence in the management of diabetes | <u>TBC</u> - T1D Global index and overview of diabetes technology present and future in lower income countries <u>Antoinette Moran</u> - Impact of CGM in East Africa, research and translation <u>Hamidah Nayaka</u> - Diabetes advocate perspective on diabetes technology in low- income countries | Alan Sinclair - Diabetes, sarcopenia and frailty: Interrelationships and clinical importance Leocadio Rodríguez Mañas - Current treatment options for sarcopenia in the context of frail older people with diabete Tali Cukierman-Yaffe - How to measure and monitor sarcopenia and frailty TBC - Is it possible to enhance the anabolic signal in Sarcopenia? | | |

| 15:15-15:25 | Break to Change Halls |
|-------------|--|
| 15:25-16:25 | PLENARY 3 |
| | CURE OF DIABETES |
| | |
| | Michael Haller - Cost effectiveness of immune therapies in preserving beta cell function – Real world applications |
| | Jay Skyler - Stem cell approaches to type 1 diabetes |
| | Michael Rickels - Islet cell therapy vs. closed loop insulin delivery for type 1 diabetes |
| 16:25-17:00 | CLOSING REMARKS |
| 17:00 | FAREWELL REFRESHMENTS |